



Vivimed

Date:13/08/2013

To

BSE Limited
Listing Department
P.J.Towers,Dalal Street,
Mumbai – 400001

National Stock Exchange of India Ltd
Listing Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra(E),Mumbai – 400051

BSE - Code : 532660

NSE- Symbol: VIVIMEDLAB

Dear Sir/Madam

Sub: Outcome of the Meeting of the Board of Directors of the Company – reg

The Board of Directors of the Company at its meeting held on August 13, 2013, inter alia, have resolved and taken note of/approved the following :

1. Pursuant to clause 41 of Listing Agreement entered into with the stock exchanges, considered and approved the submission of the Unaudited financial results for the Quarter ended June 30,2013 attached herewith;

An earnings related presentation including business highlights will be uploaded on the company's website www.vivimedlabs.com

You are requested to take note of the above.

Yours faithfully

For VIVIMED LABS LTD


SANTOSH VARALWAR
MANAGING DIRECTOR & CEO




VIVIMED LABS LIMITED
CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30th, 2013

Sl. No.	Particulars	In Lakhs			
		3 Months ended 30-06-2013 (Q1FY14)	Preceding 3 Months ended 31.03.2013 (Q4FY13)	3 Months ended 30-06-2012 (Q1FY13)	Previous Year ended 03-2013 (FY13) 31-
1	Income from Operations	(Unaudited)	(Audited)	(Unaudited)	(Audited)
	(a) Net Sales / Income from Operations (Net of Excise Duty)	34,075.44	29,807.04	27,251.66	1,10,879.56
	(b) Other Operating Income	316.03	(194.05)	180.85	1,187.35
	Total Income from Operations (Net)	34,391.47	29,612.99	27,432.52	1,12,066.91
	a. Cost of Raw Materials Consumed	15,039.05	13,285.32	13,969.45	53,743.28
	b. Purchase of Stock in Trade	-	-	-	-
	c. Changes in Inventories of finished Inventories of Finished Goods, Work-in-Progress and Stock in Trade	2,717.58	81.06	(2,974.65)	(2,415.90)
	d. Employee Benefit Expenses	1,556.09	1,435.33	1,424.33	5,032.73
	e. Depreciation and Amortisation Expenses	1,465.42	1,632.11	1,413.00	5,881.08
	f. Other Expenditure	10,195.31	10,290.01	8,819.42	35,944.97
	2 Total Expenses	30,973.45	26,723.83	22,651.54	98,186.17
	3 Profit / (Loss) from Operations before Other Income, Finance Costs and exceptional items (1 - 2)	3,418.03	2,889.16	4,780.97	13,880.75
	4 Other Income	-	-	-	-
	5 Profit / (Loss) from Ordinary Activities before Finance Costs and exceptional items (3 - 4)	3,418.03	2,889.16	4,780.97	13,880.75
	6 Finance Costs	985.65	501.85	1,589.06	4,093.18
	7 Profit / (Loss) from Ordinary Activities after Finance Costs but before exceptional items (5 - 6)	2,432.37	2,387.31	3,191.92	9,787.57
	8 Exceptional Items	-	-	-	-
	9 Profit / Loss from ordinary activities before Tax (7 - 8)	2,432.37	2,387.31	3,191.92	9,787.57
	10 Tax Expenses	433.92	888.40	578.94	1,429.15
	11 Net Profit / Loss from ordinary activities after Tax (9 - 10)	1,998.46	1,498.91	2,612.98	8,358.42
	12 Extraordinary Items (net of tax expenses Rs. Tax)	-	-	-	-
	13 Net Profit / Loss for period (11 - 12)	1,998.46	1,498.91	2,612.98	8,358.42
	14 Share of Profit / (Loss) of associates	-	-	-	-
	15 Minority Interest	-	-	-	-
	16 Net Profit / Loss after taxes, Minority Interest and share of Profit / (Loss) of Associates (13 - 14 - 15)	1,998.46	1,498.91	2,612.98	8,358.42
	17 Paid up Equity Share Capital (Face value of the Share shall be indicated)	1,606.09	1,606.09	1,393.90	1,606.09
	18 Reserve excluding Revaluation Reserves as per Balance Sheet of Previous Accounting Year	-	32,653.80	-	32,653.80
	19 Earnings per Share (before Extraordinary Items) (of Rs.10/- each) (not annualised)	12.44	9.33	18.75	52.04
	(a) Basic	12.44	9.33	18.75	52.04
	(b) Diluted	12.44	9.33	16.27	52.04

- The above Consolidated Unaudited Financial Results for the Quarter ended June 30, 2013 have been reviewed by Audit Committee and taken on record by Board of Directors at their meeting held on 13th August, 2013.
- Consolidated Financial Statements have been prepared in accordance with Accounting Standard 21 issued by ICAI. Consolidated Results are combined numbers of Vivimed Labs Limited and its direct wholly owned subsidiaries, viz., (i) Creative Healthcare Private Limited, (ii) Vivimed Labs USA, Inc., (iii) Kar Sehen Private Limited, (iv) Octantis Nobel Labs Private Limited, (v) Vivimed Holdings Limited (vi) Vivimed Labs Mauritius Ltd and its step down subsidiaries viz. (i) Vivimed Labs Europe Limited (ii) Vivimed Labs UK Limited, (iii) Vivimed Labs Spain, S.L (iv) Union Quimica Farmaceutica S.A.U., Spain, (v) Diquita Mexico S.A. de C.V. & (vi) Holiday International Limited, UK.
- The Company opted to publish only Consolidated Financial Results. Standalone results of the Company will be available on Company's website www.vivimedlabs.com and also on BSE & NSE websites.
- As per Accounting Standard 17 on Segment Reporting (AS-17), results of the two Segments "Specialty Chemicals" and "Pharma" are reported.
- Corresponding numbers of previous period / year have been revised, regrouped, wherever necessary.

Place : Hyderabad
 Date : 13.08.2013

For **VIVIMED LABS LIMITED**

 (MANOJ KUMAR)
 MANAGING DIRECTOR & CEO



VIVIMED LABS LIMITED

SEGMENT-WISE CONSOLIDATED FINANCIAL RESULTS AND CAPITAL EMPLOYED UNDER CLAUSE - 41 OF THE LISTING

₹ in Lakhs

Particulars	Quarter Ended			Year Ended
	30.06.2013 (Unaudited)	31.03.2013 (Audited)	30.06.2012 (Unaudited)	
1. Segment Revenue (net sales/income from each segment should be disclosed under this head)				
a. Speciality Chemicals Business	9,833.75	10,286.68	8,827.26	37,038.67
b. Pharma Business	24,241.69	19,520.36	18,424.40	73,840.89
Total	34,075.44	29,807.03	27,251.66	110,879.56
Less, Inter Segment Revenue				
Net sales / Income from Operations	34,075.44	29,807.03	27,251.66	110,879.56
2. Segment Results (Profit) (+) / Loss (-) before tax and interest from each segment				
a. Speciality Chemicals Business	1,499.23	1,534.93	1,969.79	6,826.37
b. Pharma Business	1,918.79	1,354.22	2,811.19	7,054.37
Total	3,418.03	2,889.15	4,780.98	13,880.74
Less: 1. Interest	985.65	501.85	1,589.06	4,093.18
2. Other Un-allocable Expenditure				
3. Un-allocable Income				
Total Profit Before Tax	2,432.37	2,387.30	3,191.92	9,787.56
3. Capital Employed				
a. Speciality Chemicals Business	79,125.29	77,724.60	76,345.97	77,724.60
b. Pharma Business	50,135.20	51,568.93	43,094.25	51,568.93
Total	129,260.49	129,293.52	119,440.22	129,293.52

For VIVIMED LABS LIMITED

(SANTOSH KARALWAR)
MANAGING DIRECTOR & CEO

Place : Hyderabad
Date : 13.08.2013



VIVIMED LABS LIMITED
STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30th, 2013

IN Lakhs

Sl. No	Particulars	3 Months ended 30-06-2013 (Q1FY14) (Unaudited)	Preceding 3 Months ended 31.03.2013 (Q4FY13) (Audited)	3 Months ended 30-06-2012 (Q3FY13) (Unaudited)	Previous Year ended 31-03-2013 (FY13) (Audited)
1	Income From Operations				
	(a) Net Sales / Income from Operations (Net of Excise Duty)	9,850.63	10,824.98	9,116.06	42,312.51
	(b) Other Operating Income	14.85	75.01	38.93	337.93
	Total Income From Operations (Net)	9,865.48	10,899.99	9,154.99	42,650.44
	a. Cost of Raw Materials Consumed	5,405.74	5,749.37	6,475.81	24,736.98
	b. Purchase of Stock in Trade				
	c. Changes in Inventories of finished Inventories of Finished Goods, Work-in-Progress and Stock in Trade	403.39	144.48	(2,028.62)	(755.32)
	d. Employee Benefit Expenses	510.95	482.92	341.75	1,550.85
	e. Depreciation and Amortisation Expenses	406.17	582.95	372.43	1,720.68
	f. Other Expenditure	1,517.17	2,101.58	2,042.71	7,415.35
2	Total Expenses	8,243.42	9,061.30	7,204.08	34,668.54
3	Profit / (Loss) from Operations before Other Income, Finance Costs and exceptional items (1 - 2)	1,622.06	1,838.69	1,950.91	7,981.90
4	Other Income	-	-	-	-
5	Profit / (Loss) from Ordinary Activities before Finance Costs and exceptional items (3 - 4)	1,622.06	1,838.69	1,950.91	7,981.90
6	Finance Costs	583.53	480.87	895.01	2,843.78
7	Profit / (Loss) from Ordinary Activities after Finance Costs but before exceptional items (5 - 6)	1,038.53	1,357.82	1,055.90	5,138.11
8	Exceptional items	-	-	-	-
9	Profit / Loss from ordinary activities before Tax (7 - 8)	1,038.53	1,357.82	1,055.90	5,138.11
10	Tax Expenses	207.71	471.72	211.18	1,464.55
11	Net Profit / Loss from ordinary activities after Tax (9 - 10)	830.82	886.10	844.72	3,673.56
12	Extraordinary Items (net of tax expenses Rs.....Lacs)	-	-	-	-
13	Net Profit / Loss for period (11 - 12)	830.82	886.10	844.72	3,673.56
14	Share of Profit / (Loss) of associates	-	-	-	-
15	Minority Interest	-	-	-	-
16	Net Profit / Loss after taxes, Minority Interest and share of Profit / (Loss) of Associates (13 - 14 - 15)	830.82	886.10	844.72	3,673.56
17	Paid up Equity Share Capital (Face value of the Share shall be indicated)	1,606.09	1,606.09	1,393.39	1,606.09
18	Reserve excluding Revaluation Reserves as per Balance Sheet of Previous Accounting Year	26,101.45	-	-	26,101.45
19	Earnings per Share (before Extraordinary Items) (of Rs.10/- each) (not annualised)	5.17	5.52	6.06	22.87
	(a) Basic	5.17	5.52	6.06	22.87
	(b) Diluted	5.17	5.52	5.26	22.87

- The above Standalone Unaudited Financial Results for the Quarter ended June 30th June, 2013 have been reviewed by Audit Committee and taken on record by Board of Directors at their meeting held on 13th August 2013.
- The Company opted to publish only Consolidated Financial Results. Standalone results of the Company will be available on Company's website www.vivimedlabs.com and also on BSE & NSE websites.
- As per Accounting Standard 17 on Segment Reporting (AS-17), results of the two segments "Specialty Chemicals" and "Pharma" are reported.
- Corresponding numbers of previous period / year have been revised, regrouped, wherever necessary.

For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)
 MANAGING DIRECTOR & CEO

Place : Hyderabad
 Date : 13.08.2013



VIVIMED LABS LIMITED

SEGMENT-WISE STANDALONE FINANCIAL RESULTS AND CAPITAL EMPLOYED UNDER CLAUSE - 41 OF THE LISTING AGREEMENT

₹ in Lakhs

Particulars	Quarter Ended			Year Ended
	30.06.2013 (Unaudited)	31.03.2013 (Audited)	30.06.2012 (Unaudited)	
1. Segment Revenue (net sales/income from each segment should be disclosed under this head)				
a.Speciality Chemicals Business	7,575.10	8,580.57	6,848.02	32,864.44
b.Pharma Business	2,275.53	2,244.41	2,268.04	9,448.07
Total	9,850.63	10,824.98	9,116.06	42,312.51
Less, Inter Segment Revenue				
Net sales / Income from Operations	9,850.63	10,824.98	9,116.06	42,312.51
2. Segment Results (Profit) (+) / Loss (-) before tax and interest from each segment				
a.Speciality Chemicals Business	1,177.90	1,605.39	1,524.61	6,410.83
b.Pharma Business	444.17	233.29	426.30	1,571.07
Total	1,622.06	1,838.68	1,950.91	7,981.90
Less: 1.Interest	583.53	480.87	895.01	2,843.78
2. Other Un-allocable Expenditure				
3. Un-allocable Income				
Total Profit Before Tax	1,038.53	1,357.82	1,055.90	5,138.11
3. Capital Employed				
a.Speciality Chemicals Business	81,509.27	77,019.49	72,547.15	77,019.49
b.Pharma Business	7,642.99	7,554.32	7,264.00	7,554.32
Total	89,152.26	84,573.81	79,811.15	84,573.81

For VIVIMED LABS LIMITED

Place : Hyderabad
Date : 13.08.2013

(SANTOSH VARALWAR)
MANAGING DIRECTOR & CEO



Part II

Select Information for the Quarter Ended 30/06/2013

	Particulars	3 months ended 30/06/2013	Preceding 3 months ended 31/03/2013	Correspondin g 3 months ended 30/06/2012	Previous Year ended 31/03/2013
A	PARTICULARS OF SHAREHOLDING				
1	Public shareholding				
	Number of Shares	9664136	9682136	76,41,739	9682136
	Percentage of Shareholding	60.17	60.28	54.84	60.28
	Promoter and Promoter Group Shareholding				
	(a) Pledged/ Encumbered				
	Number of Shares	24,52,455	22,52,455	12,52,455	22,52,455
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	38.34	35.31	19.90	35.31
	Percentage of shares (as a % of the total share capital of the company)	15.27	14.03	8.99	14.03
	(b) Non -encumbered				
	Number of Shares	39,44,335	41,26,335	50,39,748	41,26,335
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	61.66	64.69	80.10	64.69
	Percentage of shares (as a % of the total share capital of the company)	24.56	25.69	36.17	25.69

	Particulars	3 months ended 30/06/2013
B	Pending at the beginning of the quarter	Nil
	Received during the quarter	Nil
	Disposed of during the quarter	Nil
	Remaining unresolved at the end of the quarter	Nil

For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)
MANAGING DIRECTOR & CEO



Place : Hyderabad
Date : 13.08.2013